Physician profile
Dillon Stephen Smith
NPI 1245722917
$2,276.68
in general payments reported to CMS, 2019-2025
20 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $316 · 2021: $600 · 2022: $413 · 2023: $299 · 2024: $335 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $780.31 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $574.56 | 2022-2025 | Acuvue |
| Novartis Pharmaceuticals Corporation | $242.91 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $237.35 | 2020-2022 | |
| Alcon Vision LLC | $226.35 | 2019-2024 | Total30, Dailies Total1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $208.28 | 2019-2021 | |
| Allergan, INC. | $150.09 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $117.75 | 2022-2024 | Miebo |
| Rxsight INC | $107.14 | 2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Sun Pharmaceutical Industries INC. | $106.64 | 2020-2021 | |
| Biotissue Holdings INC. | $42.38 | 2021 | |
| Oyster Point Pharma, INC. | $42.34 | 2022 | |
| Eyevance Pharmaceuticals LLC | $37.14 | 2021-2022 | |
| Shire North American Group INC | $36.97 | 2019 | |
| Abbvie INC. | $36.72 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $24.02 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $23.18 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $21.77 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $20.23 | 2021 | |
| Abb Con-Cise Optical Group LLC | $12.35 | 2020 | |
| New World Medical,INC. | $8.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dillon Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.